Roche wins FDA OK for targeted drug in early lung cancer

The Food and Drug Administration has made a medicine from Roche the first specifically available for early treatment of lung tumors driven by a well-known cancer gene.

On Thursday, the agency cleared use of the drug, Alecensa, after surgical removal of a tumor in patients whose non-small cell lung cancer is positive for mutations in a gene called ALK.